6533b7d0fe1ef96bd125ae66
RESEARCH PRODUCT
Targeting the tumor mutanome for personalized vaccination therapy
ÖZlem TüreciUgur SahinJohn C. CastleSebastian Kreitersubject
next generation sequencingSomatic cellbusiness.industryImmunologyBioinformaticscancer immunogenicityDNA sequencingEpitopeVaccinationOncologyImmunizationIn vivoImmunogenic tumornon-synonymous mutationsCancer researchindividualized therapyImmunology and AllergyMedicinetumor mutationsB16f10 melanomacancer vaccinationbusinessAuthor's Viewdescription
Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-08-01 | OncoImmunology |